Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN81,2181,24-1,65
Msft1,77
Nokia3,8013,903-1,67
IBM-1,39
Mercedes-Benz Group AG51,5351,55-0,71
PFE-3,98
13.09.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 12.09.2025 17:30:41
Zur Rose Group N (Swiss Exchange)
Závěr k 12.9.2025 Změna (%) Změna (CHF) Objem obchodů (CHF)
6,27 3,04 0,19 1 598 368
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 13.09.2025
Popis společnosti
Obecné informace
Název společnostiDocMorris AG
TickerDOCM
Kmenové akcie:Ordinary Shares
RICDOCM.S
ISINCH0042615283
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.06.2025
Počet zaměstnanců k 31.12.2024 1 454
Akcie v oběhu k 02.07.2025 38 182 375,24
MěnaCHF
Kontaktní informace
UliceWalzmuehlestrasse 49
MěstoFRAUENFELD
PSČ8500
ZeměSwitzerland
Kontatní osobaDaniel Grigat
Funkce kontaktní osobyHead of Investor Relations and Sustainability
Telefon41 527 240 020
Fax41527240015
Kontatní telefon41 525 605 810

Business Summary: DocMorris AG, formerly Zur Rose Group AG, is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. DocMorris operates at the healthcare, technology and e-commerce, with a primary focus on customer-centric digital healthcare and improving medication efficacy. core business is online pharmacy. In addition to prescription medicines (Rx), assortment features over-the-counter (OTC) and consumer health as well as beauty and personal care (BPC) products. Private labels, including nutritional supplements, painkillers, first-aid products and other OTC medicines. The Company's operates under brands such as PromoFarma, DoctiPharma, Apotal, Medpex and Teleclinic, among others
Financial Summary: BRIEF: For the six months ended 30 June 2025, DocMorris AG revenues increased 9% to SF541.5M. Net loss increased 62% to SF61.6M. Revenues reflect Germany segment increase of 9% to SF508M, Europe segment increase of 3% to SF33.5M, Germany segment increase of 9% to SF508M, Europe segment increase of 3% to SF33.5M. Higher net loss reflects Other Operating Expenses increase of 25% to SF103M (expense), Finance income decrease of 96% to SF590K (income).
Odvětvová klasifikace
TRBC2012Drug Retailers (NEC)
MGINDUSTRYMajor Drugs
MGSECTORHealthcare
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICSPharmacies and Drug Retailers
NAICSAll Other Miscellaneous Retailers
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Pharmacies and Drug Stores
NAICS2007Electronic Shopping
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
NAICS1997Pharmacies and Drug Stores
NAICS1997Electronic Shopping and Mail-Order Houses
SICDrugs/proprietaries/sundries
SICDrug Stores/proprietary Stores
SICMisc Retail Stores, Nec



  • Poslední aktualizace: 13.09.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Member of the Executive Board, Head GermanyWalter Hess6022.11.202301.03.2015
Chief Financial OfficerDaniel Wueest5501.10.202401.10.2024
Chief Operations Officer, Member of the Executive BoardKaspar Niklaus5701.11.202201.11.2022
Chief Technology OfficerPablo Ros Gomez4301.11.202401.11.2024
Head - Europe, Member of the Executive BoardDavid Maso5401.05.2020